{"title":"Radioimmunotherapy of acute myeloid leukemia: a critical assessment of its prospects and limitations.","authors":"Donald Bunjes","doi":"10.1080/17474086.2025.2449863","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Leukemic stemcells (LSC) are the source of relapse in acute myeloid leukemia (AML). Thus,eliminating LSC is one of the overarching goals of AML research. Radioimmunotherapyis an immunotherapeutic approach which utilizes radioactive isotopes aseffector molecules based on the proven ability of ionizing radiation (IR) tokill LSC.It has the potential to eliminate target - antigen negative LSC.</p><p><strong>Areas covered: </strong>LSC biology,radiobiological principes of RIT, an overview of published and unpublishedclinical results of RIT in AML. Issues of practical implementation of RIT inclinical trials.</p><p><strong>Expert opinion: </strong>RIT for AML isat a critical juncture. Its ability to target antigen negative LSC gives it anadvantage compared with other forms of immunotherapy. In order to compete withother forms of targeted therapy the procedure has to be simplified.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2449863","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Leukemic stemcells (LSC) are the source of relapse in acute myeloid leukemia (AML). Thus,eliminating LSC is one of the overarching goals of AML research. Radioimmunotherapyis an immunotherapeutic approach which utilizes radioactive isotopes aseffector molecules based on the proven ability of ionizing radiation (IR) tokill LSC.It has the potential to eliminate target - antigen negative LSC.
Areas covered: LSC biology,radiobiological principes of RIT, an overview of published and unpublishedclinical results of RIT in AML. Issues of practical implementation of RIT inclinical trials.
Expert opinion: RIT for AML isat a critical juncture. Its ability to target antigen negative LSC gives it anadvantage compared with other forms of immunotherapy. In order to compete withother forms of targeted therapy the procedure has to be simplified.
期刊介绍：
Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
